|
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC). |
|
|
Research Funding - BioMed Valley Discoveries (Inst); Lilly (Inst); Verastem (Inst) |
|
|
Consulting or Advisory Role - Merrimack; Rafael Pharmaceuticals |
Research Funding - Advaxis (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Oncolytics (Inst); Roche (Inst); Synta (Inst) |
|
|
Employment - Memorial Sloan-Kettering Cancer Center |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; EMD Serono; Exelixis; Genentech/Roche; Guardant Health; Guerbet; Halozyme; Helsinn Healthcare; Immunogen; IntegraGen; Lexicon; Lilly; Novartis; Oncosil; Opsona Therapeutics; Pfizer; Purdue Pharma; Rafael Pharmaceuticals; Taiho Pharmaceutical; TRM Oncology |
Research Funding - Acerta Pharma; advanced accelerator applications (Inst); Bristol-Myers Squibb; Celgene; Infinity Pharmaceuticals (Inst); MedImmune; Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Xencor; Xencor |
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Dava Oncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn Healthcare; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical |
|
|
Employment - Taiho Pharmaceutical |
Leadership - Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Taiho Pharmaceutical |
|
|
Employment - Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Honoraria - genentech; Nestle health science |
Consulting or Advisory Role - Aduro Biotech; BeiGene; Celgene; Cornerstone Pharmaceuticals; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; Opsona Therapeutics; Pierre Fabre; Symphony Evolution |
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst) |
Travel, Accommodations, Expenses - Celgene; EMD Serono; Genentech/Roche; Nestle health science |
Other Relationship - AstraZeneca; Symphony Evolution |
|
|
Consulting or Advisory Role - McNeil PPC (I) |
Research Funding - Taiho Pharmaceutical |